289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)
暂无分享,去创建一个
P. Rougier | J. Raoul | M. Peeters | E. Mitry | C. Brézault | J. V. Laethem | L. Cals | F. Husseini | J. Vedovato | M. Mueser | J. Laethem